Loading
Life sciences · Journal article
Cancer · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: Liposomal irinotecan, characterized by its favorable pharmacologic properties and reduced systemic toxicity compared to irinotecan, has demonstrated superior therapeutic potential. This multicenter, single-arm study was conducted to evaluate the efficacy and safety of liposomal irinotecan, capecitabine, and bevacizumab as a second-line treatment for metastatic colorectal cancer (mCRC). METHODS:, twice daily, d1-10), and bevacizumab (5 mg/kg, d1). The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, disease control rate, duration of response, overall survival, and safety. RESULTS: Between March 2024 and July 2024, 63 patients were enrolled, with a median age of 60.0 years (range: 37.0-79.0). Among the patients who received at least one tumor assessment, the objective response rate and disease control rate were 22.9% (11/48; 95% CI, 12.0-37.3) and 89.6% (43/48; 95% CI, 77.3-96.5), respectively. With a median follow-up of 16.2 months (range: 0.5-28.5), the median progression-free survival was 8.1 months (95% CI, 7.3-8.9), and the median overall survival was 19.5 months (95% CI, 15.2-23.8). The most common grade 3 to 4 adverse events were diarrhea (12.7%), neutropenia (11.1%), and fatigue (6.3%). CONCLUSIONS: The combination of liposomal irinotecan, capecitabine, and bevacizumab demonstrated promising antitumor activity and a manageable safety profile in patients with mCRC who had failed first-line oxaliplatin-based therapy. These results suggested that this regimen is a clinically feasible second-line treatment option for mCRC.